1. Zhang, Jinghui, Ding, Li, Holmfeldt, Linda, Downing, James R, Mullighan, Charles G. 2012. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. In Nature, 481, 157-63. doi:10.1038/nature10725. https://pubmed.ncbi.nlm.nih.gov/22237106/
2. Tokgun, Pervin Elvan, Karagenc, Nedim, Karasu, Uğur, Akca, Hakan, Yüksel, Selçuk. 2023. Treatment of STING-associated vasculopathy with onset in infancy in patients carrying a novel mutation in the TMEM173 gene with the JAK3-inhibitor tofacitinib. In Archives of rheumatology, 38, 461-467. doi:10.46497/ArchRheumatol.2023.9927. https://pubmed.ncbi.nlm.nih.gov/38046254/
3. Velatooru, Loka Reddy, Hu, Cheng Hui, Bijani, Pedram, Duvic, Madeleine, Ni, Xiao. 2023. New JAK3-INSL3 Fusion Transcript-An Oncogenic Event in Cutaneous T-Cell Lymphoma. In Cells, 12, . doi:10.3390/cells12192381. https://pubmed.ncbi.nlm.nih.gov/37830594/
4. Mittempergher, Lorenza, Piskorz, Anna M, Bosma, Astrid J, Brenton, James D, Bernards, René. 2020. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. In PloS one, 15, e0235766. doi:10.1371/journal.pone.0235766. https://pubmed.ncbi.nlm.nih.gov/32639993/
5. Xu, P P, Zhou, T, Xu, Y Y, Ouyang, J, Chen, B. . [Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review]. In Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 45, 872-875. doi:10.3760/cma.j.cn121090-20240412-00138. https://pubmed.ncbi.nlm.nih.gov/39414615/
智鼠故事 
